Teclison is to develop new drugs to treat cancer and other diseases with strong unmet medical needs.
Teclison has raised $5.9M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in February 2022.
Teclison's investors include Nestor Capital, WTT Investment.
Teclison is headquartered in Montclair, United States.
Teclison is to develop new drugs to treat cancer and other diseases with strong unmet medical needs.
Teclison is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Teclison — Funding & Investors." VCBacked, February 14, 2022, https://www.vcbacked.co/company/teclison. Accessed September 29, 2026.
VCBacked. (2022). Teclison — Funding & Investors. Retrieved September 29, 2026, from https://www.vcbacked.co/company/teclison
{{cite web |title=Teclison — Funding & Investors |url=https://www.vcbacked.co/company/teclison |website=VCBacked |access-date=September 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated